Published

European regulator issues negative advice on American-approved Alzheimer's drug

Summary by NRC Handelsblad
The medicine works differently than existing ahlzeimer medications and slightly slows cognitive decline in patients. But according to the EMA, the risk of side effects is too great.
Think freely.Subscribe and get full access to Ground NewsSubscriptions start at $9.99/yearSubscribe

Bias Distribution

  • 100% of the sources lean Left
100% Left
Factuality

To view factuality data please Upgrade to Premium

Ownership

To view ownership data please Upgrade to Vantage

Sources are mostly out of (0)

You have read out of your 5 free daily articles.

Join us as a member to unlock exclusive access to diverse content.